Newsroom

LATEST PUBLICATIONS

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

2024-08-02T14:22:45-07:00March 7th, 2023|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

2023-04-10T20:24:04-07:00March 2nd, 2023|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

2022-12-29T21:22:21-08:00November 15th, 2022|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

2022-12-29T21:19:31-08:00June 4th, 2022|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

2023-01-08T18:20:36-08:00May 30th, 2022|

Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML

2022-10-24T14:57:12-07:00October 24th, 2022|

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

2026-03-08T22:24:18-07:00August 16th, 2022|

Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine

2025-08-26T08:08:16-07:00May 9th, 2022|

Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline Use

2026-03-09T18:50:30-07:00September 2nd, 2021|

Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in China

2021-07-22T17:27:56-07:00July 22nd, 2021|

SOHO

Sep 9-12, 2026
Houston, TX
Exhibiting
Visit Conference Website

European Congress of Pathology (ECP 2026)

Sep 12-16, 2026
Stockholm, Sweden
Attending
Visit Conference Website

AGBT Precision Health

Sep 14-16, 2026
San Diego, CA
Exhibiting
Visit Conference Website

iwAL Meeting

Sep 18-20, 2026
Cambridge, MA
Attending
Visit Conference Website

NCCN Annual Hematologics Malignancies Congress

Sep 18-19, 2026
New York, NY
Attending
Visit Conference Website

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Newsroom

Newsroom

LATEST PUBLICATIONS

LATEST PRESS

CONFERENCES

SOHO

European Congress of Pathology (ECP 2026)

AGBT Precision Health

iwAL Meeting

NCCN Annual Hematologics Malignancies Congress

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.